CME Presentations

HER2 Low in Breast Cancer


Presentations


Speakers


CME Information

PIM LogoPQH Logo

Classification and Management of the HER2-Low Breast Cancer Subtype

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the National Breast Cancer Foundation, Inc.

ACKNOWLEDGEMENT

Supported by independent educational grants from AstraZeneca and Daiichi Sankyo Inc.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-148-L01-P)
Type of Activity: Knowledge

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-149-H01-P)
Type of Activity: Knowledge

Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

DATE OF RELEASE/EXPIRATION

Live Activity

Monday, March 28, 2022, at 11:00 am - 12:00 pm EST

Enduring Material

March 28, 2022 - March 28, 2023

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Review emerging evidence regarding appropriate methods for testing and interpreting HER2-low breast cancer based on recommended assays
  • Facilitate multidisciplinary cooperation to reduce variability in approaches to management of patients with HER2-low breast cancer
  • Evaluate evidence supporting new and emerging ADCs in HER2-low breast cancer
  • Discuss recommended techniques for mitigating specific adverse events related to ADC therapy

TARGET AUDIENCE

The intended audience for this activity program are medical oncologists, breast oncologists, gynecologists, surgeons, pathologists, oncology pharmacists, and other clinicians involved in the management of patients with HER2-low breast cancer.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com.To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Ian E. Krop, MD PhD
Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research
Director of the Yale Cancer Center Clinical Trials Office
New Haven, CT
Grant/Research Support: Genentech, Macrogenics, Pfizer (Clinical trial support paid to my institution)
Consultant/Advisory Board: AstraZeneca, Bristol Meyers Squibb, Daiichi Sankyo, Genentech/Roche Macrogenics, Taiho Oncology, and Seattle Genetics
Dara S. Ross, MD
Associate Attending
Department of Pathology Memorial Sloan-Kettering Cancer Center
New York, NY
Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive.com.com or ClinicalSeriesLive.com at 1-877-394-1306 or at Support@OMedLive.com.